Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise, and for weight management in adults with obesity or overweight with weight-related comorbidities
Since 2010, it has technically remained the only truly FDA-approved treatment specifically indicated for the treatment of chronic migraine prevention, up until Qulipta (Atogepant) became the first and only pill to receive FDA approval for chronic migraine in 2023
TGF-1 is researched for its role in cell proliferation, differentiation, and apoptosis
The maximum dose studied in clinical trials is 12 mg weekly
[1] [2] However, whilst there is no pharmacological contraindication to taking these medications together, both drugs can affect the gastrointestinal system in different ways, which warrants consideration
Nonparametric tests such as the MannWhitney U test or the KruskalWallis test were used to analyse data that were not normally distributed
